MAPK-IN-4

MAPK-IN-4 (Compound c1) is an orally active anti-inflammatory agent. MAPK-IN-4 can inhibit the expression and release of pro-inflammatory cytokines IL-6 and TNF-α induced by LPS (HY-D1056) . MAPK-IN-4 can bind to IRAK4 and exert its anti-inflammatory effect by inhibiting the MAPK pathway[1].

Product Specifications

UNSPSC

12352005

Target

Interleukin Related; IRAK; p38 MAPK

Related Pathways

Immunology/Inflammation; MAPK/ERK Pathway

Field of Research

Inflammation/Immunology

Smiles

N[C@@H]1CC[C@H](OC2=C3C=C(OC)C(OCC4=CC=CC(Br)=C4)=CC3=NC=N2)CC1

Molecular Formula

C22H24BrN3O3

Molecular Weight

458.35

References & Citations

[1]Guo M, et al. Anti-inflammatory agents design via the fragment hybrid strategy in the discovery of compound c1 for treating ALI and UC. Eur J Med Chem. 2025 Feb 25;289:117431.